Publications in Peer-Reviewed Journals: SCiAN’s best-in-class trial design, data management and biostatistics support acknowledged

SCiAN Services, Inc., a North American Clinical Data
Management – Biostatistics CRO and EDC solution provider acknowledges the following 3
successful publications in peer-reviewed journals in 2014:

Hauser RA, Olanow CW, Kieburtz KD, Pourcher E, Docu-Axelerad A, Lew M, Kozyolkin O,
Neale A, Resburg C, Meya U, Kenney C, Bandak S. “Tozedenant (SYN115) in patients with
Parkinson’s disease who have motor fluctuations on levodopa: a phase 2b, double-blind,
randomized trial”. The Lancet Neurology, 2014 Vol. 13 No. 8 pp. 767-776

Bottcher B, Laterza RM, Wildt, L, Seufert RJ, Buhling KJ, Singer CF, Hill W, Griffin P,
Jilma B, Schulz M, Smith RP. “A first-in-human study of PDC31 (prostaglandin F2a
receptor inhibitor) in primary dysmenorrheal”. Human Reproduction 2014 Vol. 0 No. 0 pp.
1-9 doi: 10.1093/humrep/deu205.

Zaltzman JS, Lai V, Schulz M, Moon KH, Cherney DZ. “A randomized cross-over
comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily
tacrolimus on renal function in healthy volunteers”. Transplant International, 2014 doi:
10.1111/tri.12435.

In recognizing the sponsors on their accomplishment, Dr. Miklos Schulz, President and CEO of
SCiAN Services, Inc. said: “We also want to thank Biotie Therapies, PDC Biotech, and Astellas
Global for the opportunity of being part of their clinical development program and extend our
continuous commitment to supporting their innovative programs. The professional team at SCiAN
shares their excitement in having been an integral part and contributor of best-in-class trial design,
data management and biostatistics.”